Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC.

Prostate. 2014 Feb;74(2):201-9. doi: 10.1002/pros.22741. Epub 2013 Oct 16.

2.

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC.

Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.

PMID:
25970160
3.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16.

4.

PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.

Itsumi M, Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

J Mol Endocrinol. 2014 Aug;53(1):31-41. doi: 10.1530/JME-13-0303. Epub 2014 Apr 29.

5.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

6.

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813. Epub 2014 Apr 17.

PMID:
24740858
7.

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22.

8.

Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells.

Hahm ER, Singh SV.

Cancer Prev Res (Phila). 2010 Apr;3(4):484-94. doi: 10.1158/1940-6207.CAPR-09-0250. Epub 2010 Mar 16.

9.

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC.

Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.

10.

Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Song Y, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Clin Cancer Res. 2014 Feb 15;20(4):951-61. doi: 10.1158/1078-0432.CCR-13-1809. Epub 2013 Dec 18.

11.

The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.

Kregel S, Szmulewitz RZ, Vander Griend DJ.

Prostate. 2014 Nov;74(15):1530-43. doi: 10.1002/pros.22870. Epub 2014 Aug 31.

12.

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.

13.

The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac.

Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jun;107(6):826-36. doi: 10.1016/j.tripleo.2008.12.054. Epub 2009 Mar 9. Retraction in: Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Dec;118(6):746.

PMID:
19272804
14.

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.

Eur Urol. 2015 Jun;67(6):986-90. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.

PMID:
25151012
15.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
16.

Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity.

Kim JK, Kim JY, Kim HJ, Park KG, Harris RA, Cho WJ, Lee JT, Lee IK.

PLoS One. 2013 Nov 15;8(11):e80391. doi: 10.1371/journal.pone.0080391. eCollection 2013.

17.

Diallyl trisulfide inhibits activation of signal transducer and activator of transcription 3 in prostate cancer cells in culture and in vivo.

Chandra-Kuntal K, Singh SV.

Cancer Prev Res (Phila). 2010 Nov;3(11):1473-83. doi: 10.1158/1940-6207.CAPR-10-0123. Epub 2010 Oct 19.

19.

Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.

Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, Hong Z.

Oncotarget. 2014 Sep 30;5(18):8416-28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk